Drilldown: Medicines

None (2)

Other values:

Search

None (69) · Delysid (historical, Sandoz, withdrawn 1965) (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) · Zulresso (1) · Zurzuvae (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antipsychotic · Antiparkinsonian · Empathogen · Neuroleptic · Cathinone

Other values:

Search

None (1) · 1-acetyl-LSD; prodrug of LSD (1) · 5-HT2A agonist (26) · 5-HT2A agonist; D2 partial agonist (1) · 5-HT2A agonist; long duration (1) · 5-HT2A agonist; MAO inhibitor (1) · 5-HT2A agonist; milder than other 2C-x (1) · 5-HT2A agonist; minor psilocybin mushroom alkaloid (1) · 5-HT2A agonist; primarily auditory effects (1) · 5-HT2A agonist; sigma-1 agonist (1) · 5-HT2A partial agonist (2) · Contains bufotenin and DMT (1) · Contains LSA (2) · Contains mescaline (2) · Contains psilocybin and psilocin (1) · DMT + MAOI (harmine/harmaline); 5-HT2A agonist (1) · Extremely potent 5-HT2A agonist; vasoconstrictor (1) · Extremely potent 5-HT2A agonist; very long duration (1) · LSD analogue; 5-HT2A agonist (4) · Lysergic acid 2,4-dimethylazetidide; 5-HT2A agonist (1) · Lysergic acid hydroxyethylamide; 5-HT2A agonist (1) · Monoamine releasing agent; 5-HT2A agonist (1) · Potent 5-HT2A agonist (5) · Potent 5-HT2A agonist; no oral activity (1) · Potent 5-HT2A agonist; sigma-1 agonist (1) · Potent 5-HT2A agonist; very long duration (1) · Prodrug of 4-HO-DET; 5-HT2A agonist (1) · Prodrug of 4-HO-DiPT; 5-HT2A agonist (1) · Prodrug of 4-HO-MET; 5-HT2A agonist (1) · Prodrug of 4-HO-MiPT; 5-HT2A agonist (1) · Prodrug of LSD; 5-HT2A agonist (4) · Prodrug of psilocin; 5-HT2A agonist (1) · Serotonin/dopamine/norepinephrine releasing agent; 5-HT2A agonist (1) · Synthetic neuroactive steroid (an analog of allopregnanolone), bioavailable orally unlike brexanolone. Positive allosteric modulator at GABA-A receptors including extrasynaptic δ-containing subtypes. (1) · Very potent 5-HT2A agonist; long duration (1)

None (71) · Postpartum depression (PPD) in adults (1) · Postpartum depression (PPD) in adults (FDA-approved 2023) (1)

None (71) · 50 mg PO once daily with fatty food in the evening × 14 days (1) · Single 60-hour continuous IV infusion: 30 mcg/kg/h × 4h → 60 mcg/kg/h × 20h → 90 mcg/kg/h × 28h → 60 mcg/kg/h × 4h → 30 mcg/kg/h × 4h (1)

None (71) · 100 mg/20 mL vial, single-use (1) · 20 mg, 25 mg, 30 mg capsules (1)

None (71) · 50 mg/d × 14 d (1) · Single 60-hour course (1)

None (69) · insufflated (1) · Intravenous (continuous infusion in a REMS-certified facility) (1) · Oral (3) · PR (1)

None (69) · 30–60 minutes (1) · 45-75 min (oral) (1) · Antidepressant effect within hours of infusion start; sustained at 30 days (1) · Day 3 of dosing in trials; sustained through day 45 (1)

None (69) · 14-day course; effect persists after discontinuation in trials (1) · 4-8 h (1) · 8–12 hours (1) · Single infusion course (1)

None (69) · 3–5 hours (1) · Not well characterized (1) · ~16-23 hours (1) · ~9 hours (terminal) (1)

None (69) · 100% (IV) (1) · 70–90% (oral) (1) · Adequate (food-dependent, must take with fatty meal) (1) · Not well characterized (1)

None (69) · Limited data; avoid in pregnancy. Lactation: present in milk; consider risks (1) · Medicine is structurally identical to endogenous allopregnanolone; pregnancy considerations relate to breastfeeding during/after infusion. Limited data; brief interruption of breastfeeding considered (1) · Not established (2)

None (69) · Rx, Schedule IV (US) (1) · Rx; REMS program required (excessive sedation/loss of consciousness during infusion) (1) · Schedule I (United States) (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1)